Are Asthma Medications and Management Related to Deaths from Asthma?

Transcription

1 Are Asthma Medications and Management Related to Deaths from Asthma? MICHAEL J. ABRAMSON, MICHAEL J. BAILEY, FIONA J. COUPER, JAN S. DRIVER, OLAF H. DRUMMER, ANDREW B. FORBES, JOHN J. MCNEIL, E. HAYDN WALTERS and the Victorian Asthma Mortality Study Group Departments of Respiratory, Forensic, and Epidemiology and Preventive Medicine, and Victorian Institute of Forensic Medicine, Monash University, Southbank, and Monash Medical School, The Alfred Hospital, Melbourne, Australia There is controversy about the role of -agonists in asthma mortality, and the impact of asthma management plans remains unclear. We compared blood -agonist levels in patients dying from asthma with those in controls, and estimated the risks associated with specific classes of medication and patterns of management. We identified 89 asthma deaths and recruited 322 patients presenting to hospitals with acute asthma. A questionnaire was administered to the next of kin in 51 cases, and to 202 controls. Blood drawn from 35 cases and 229 controls was assayed for salbutamol. Smoking, drinking, and family problems were significantly more likely among the cases of asthma death than among the controls. The two groups were reasonably well matched with regard to markers of chronic asthma severity. of asthma death were significantly less likely than controls to use a peak flow meter. Written action plans were associated with a 70% reduction in the risk of death. Use of nebulized bronchodilators or oral steroids was significantly more likely in cases of asthma death. Mean blood salbutamol concentrations were 2.5 times higher in cases of asthma. The use of oral steroids for an attack of asthma reduced the risk of death by 90%. More widespread adoption of written asthma management plans, with less reliance on -agonists and closer medical supervision, should reduce asthma mortality. (Received in original form on October 12, 1999 and in revised form June 14, 2000) Other members of the Victorian Asthma Mortality Study Group were: Donald Campbell, John Coleridge, Nerida Evans, Andrew Maclean, Henry Pinskier, Colin Robertson, Graeme Thompson, and Jessika Willis. Supported by the National Health and Medical Research Council of Australia. Correspondence and requests for reprints should be addressed to A/Prof. Michael Abramson, Department of Epidemiology and Preventive Medicine, Monash Medical School, The Alfred Hospital, Prahran, Victoria 3181, Australia. Michael.Abramson@med.monash.edu.au Am J Respir Crit Care Med Vol 163. pp 12 18, 2001 Internet address: During the 1980s, Australia and New Zealand led the world in deaths from asthma. In Australia, the standardized mortality rate (SMR) for asthma rose to 5.8/100,000/yr in 1989 and then fell to 3.0/100,000/yr in 1996 (1). The epidemic of asthma deaths and near-fatal attacks has been investigated in both countries through case series (2, 3), case control studies (4 8), and cohort studies (9, 10). Preventable factors have included inadequate assessment or therapy, discontinuity of medical care, poor adherence with therapy, delay in seeking or receiving help, and inadequate treatment of the fatal attack (3, 4). There has been controversy about the possible relationship between inhaled -agonists and deaths in asthma. Several case control studies in New Zealand suggested that the potent and relatively non 2 -selective agonist fenoterol doubled the risk of death from asthma (5 7). The rise and fall in asthma mortality in New Zealand has been attributed to the rise and fall in the prescription of fenoterol inhalers (11). However, a cohort study conducted in the Canadian province of Saskatchewan suggested that increased asthma deaths and near deaths could be a class effect of -agonists rather than being due to the toxicity of fenoterol alone (12). Nonetheless, further analysis of the Saskatchewan data indicated that the risk of death was much greater among those patients who had only fenoterol prescribed than among those who had only salbutamol prescribed (13). One problem with both the New Zealand and Canadian studies was in the assessment of exposure to -agonists. The case control studies determined the exposure of cases from medications prescribed by general practitioners (5) or recorded in hospital notes (6, 7). In Saskatchewan, the investigators obtained exposure information from a computerized prescribing data base (12). It is well recognized that misclassification of exposure can substantially bias estimates of risk. Measurement of drug concentrations in blood should give more accurate information about actual exposure to -agonists. Increased -agonist concentrations have been reported both in patients with acute severe asthma (14) and in cases of death from asthma (15). Another concern has been the potential for confounding by severity of asthma. After performing a stratified analysis, utilizing markers of chronic asthma severity, Beasley and coworkers (16) argued that confounding alone could not explain the association between fenoterol and asthma death. The increased risk of death found in Saskatchewan also persisted after adjustment for confounding by available markers of asthma severity (17). However, a cohort study in Auckland found that the excess risk of life-threatening attacks associated with fenoterol disappeared after control was applied for the number of hospital admissions, continuous oral steroid use, severity of previous attacks, and race (9). It has since been suggested that this discrepancy may have arisen from differences in the population (older patients attending a single institution) and outcome (predominantly intensive care unit [ICU] admissions rather than deaths) (13). Good management of asthma involves much more than the prescription of -agonists. The Australian Asthma Management Plan (AAMP) advises physicians to assess asthma severity, achieve best lung function, maintain best lung function by avoiding trigger factors and optimizing medication, develop an action plan, and educate and review patients regularly (18). Key features of the AAMP have been increasingly adopted in clinical practice in Australia. Between 1990 and 1993, the proportion of adult asthma patients with both a peak flow meter (PFM) and an action plan increased significantly, as did the proportion using inhaled corticosteroids (19). However, it is not known whether these clinically desirable changes are in any way responsible for the decline in asthma mortality. We therefore undertook a case control study to compare blood -agonist levels in cases of death from asthma with those in asthmatic controls; to estimate the risk of death associated with the reported use of specific classes of medication in asthma; and to estimate the risk of death associated with particular patterns of asthma management, after allowing for confounding by severity.

2 Abramson, Bailey, Couper, et al.: Asthma Management and Mortality 13 METHODS of death from asthma were identified through the Victorian Registry of Births, Deaths and Marriages from 1994 to The inclusion criteria were that asthma appeared on the death certificate and that the age at death was 60 yr. The death certificates were reviewed by two clinicians to confirm that asthma was the underlying cause of death. We found very good interrater agreement ( 0.77 for adults and 0.94 for children) (1). There were 66 potential cases in which one clinician was unsure of the cause of death and which were reviewed by a clinical panel that had access to interviews with general practitioners (GPs) and coroner s records, including postmortem reports when these were available. In 89 cases the panel decided that asthma was the principal cause of death. A further 116 potential cases were excluded either by both clinical reviewers or by panel because death was attributed to acute myocardial infarction (n 21), ischemic heart disease with congestive cardiac failure (n 11), other cardiac conditions (n 5), chronic obstructive pulmonary disease (COPD) (n 21), pneumonia (n 14), pulmonary embolism (n 5), cystic fibrosis (CF) (n 2), malignancy (n 20), injury or poisoning (n 9), an acute cerebral event with aspiration (n 4), renal or hepatic failure (n 3), or sudden infant death syndrome (n 1). Questionnaire The GPs and/or next of kin of the case patients were interviewed with the questionnaire previously used in the South Australian asthma mortality study (20). Both interviews were completed for 41 cases, a GP interview only for 28 cases, and a next-of-kin interview only for 10 cases. The next of kin declined to be interviewed in 16 cases and were lost to follow-up in 12 cases. The next of kin participated in four cases in which the GP declined and in six cases in which no GP could be identified. Thus, some information was available for 79 (89%) of the asthma deaths. In the analyses presented in this report, the next-ofkin questionnaires served as the primary data source for demographic information, psychosocial problems, asthma morbidity, chronic asthma severity, asthma medications, and management. The next of kin were asked whether the case patients had used any inhaled medicines to help their breathing at any time in the month before death. If the answer was yes, the next of kin were shown photographs of asthma medications available in Australia at the time, and were asked two further questions: (1) Which of these medications had the patient usually taken in the last month? (2) Did the patient use any of these medications for the last attack of asthma? The replies were coded to distinguish between usual medication and medication used for the last asthma attack. Medications were classified into the five categories of: (1) inhaled symptomatic medication, which included the bronchodilators salbutamol (albuterol), fenoterol, terbutaline, ipratropium, salmeterol, adrenaline (epinephrine) or isoprenaline delivered by metered dose or dry powder inhaler; (2) nebulized symptomatic medication, which included salbutamol, ipratropium, fenoterol, or terbutaline solutions; (3) inhaled preventive medication, which included beclomethasone, budesonide, fluticasone, or cromoglycate delivered by metered dose or dry powder inhaler; (4) oral symptomatic medication, which included theophylline, salbutamol, terbutaline, or ephedrine tablets or syrups; and (5) oral preventive (steroid) medication, which included prednisolone, prednisone, betamethasone, or dexamethasone tablets. The controls were patients presenting with a principal complaint of acute severe asthma who required nebulized bronchodilators in the emergency departments of four participating hospitals in Melbourne between 1994 and The exclusion criteria were age 60 yr or documented COPD. A total of 322 potential controls were identified between 1994 and The panel excluded two controls who subsequently died from asthma and a further seven patients who were deemed to have presented primarily for treatment of COPD, bronchiectasis, CF, hyperventilation, or hernia. Two hundred and two controls (65%) and 92 of their GPs were interviewed with the South Australian questionnaire (20). Thirty-four controls declined to participate and 79 were lost to follow up; in 13 instances the controls participated but the GP declined; and in 15 instances the controls participated but no GP could be identified. The remaining GPs were not approached. Markers of acute asthma severity (arterial carbon dioxide tension [Pa CO2 ], peak expiratory flow, and serum potassium level) were extracted from hospital records whenever these investigations had been conducted. Details of ambulance attendance to both cases and controls were obtained from the records of Ambulance Service Victoria. 2 -Agonist Assays Blood was available in 35 cases referred to the coroner, either on reception of the body or during postmortem examination at the Victorian Institute of Forensic Medicine (VIFM). In addition, 229 controls underwent venipuncture for clinical purposes. 2 -Agonist assays were undertaken at the VIFM, where whole blood or plasma specimens were analyzed with gas chromatography-mass spectrometry for the simultaneous determination of salbutamol, terbutaline, and fenoterol. A solid-phase extraction procedure was used, giving a limit of quantitation of 1 ng/ml for each analyte in 1 ml of blood and plasma (21). Statistical Analysis The questionnaire responses, data extracted from hospital records, and blood salbutamol concentrations were entered into data bases generated with the dbase IV software system (Ashton Tate Corporation, Torrance, CA). The data bases were merged by subject identifiers, and range and logic checks were performed. All subsequent statistical analyses were performed with the SAS version 6.12 software package (SAS Institute, Cary, NC) (22). Categorical variables were compared in contingency tables and associations assessed with chisquare tests. The means (or medians) of continuous variables were compared with student s t tests or equivalent nonparametric tests. Estimates of the risk of death were adjusted by multiple logistic regression. All models included demographic variables (age, sex, country of birth, employment, residential address), smoking status, and psychosocial factors (drinking and family problems). The models for usual medications included hospital admissions in the last year. The models for written action plans and medications for an attack included both hospital admissions in the last year and usual oral preventive medication in the last month, to control for confounding by asthma severity. Because the distribution of blood salbutamol concentrations was highly skewed, values were log-transformed before further analysis. Multiple linear regression models were developed to adjust salbutamol concentrations for age, sex, mode of administration (inhaled/intravenous), ambulance attendance, and markers of asthma severity (hospital admissions in the last year and usual oral preventive medication). A value of p 0.05 was accepted as statistically significant. Ethics The study was approved by the Standing Committee on Ethics in Research on Humans at Monash University and by the ethics committees of the Alfred Hospital, Austin and Repatriation Medical Centre, Box Hill Hospital, Monash Medical Centre, and Victorian Institute of Forensic Medicine. Characteristic TABLE 1 DEMOGRAPHIC AND PSYCHOSOCIAL CHARACTERISTICS OF CASES AND CONTROLS (n 202) p Value Mean age, yr Sex, % male 54.9% 37.1% 0.02 Unemployed 11.8% 6.4% 0.2 Australian born 70.6% 77.2% 0.32 Current smoker 49% 33.2% 0.04 Drank alcohol upon arising in morning 9.8% 2.5% 0.02 Family problems 52.9% 23.2% 0.001

3 14 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL TABLE 2 ASTHMA MORBIDITY AND CHRONIC SEVERITY MARKERS AMONG CASES AND CONTROLS Marker (n 202) p Value Activities limited 67% 56% 0.18 Lost days from work, school, or usual activities in last year 67% 81% 0.03 Frightening attack in last month 79% 78% 0.87 Woken from sleep in last month 83% 78% 0.43 Persistent asthma 46.4% 13.6% Ever admitted to hospital 18.2% 27.9% 0.14 Admitted to hospital in last year 17.1% 25.3% 0.12 Admitted to intensive care unit in last year 38% 26% 0.1 Admitted to hospital in last month 8.3% 30% RESULTS Description of and Demographic and psychosocial characteristics of the cases and controls are described in Table 1. The case patients were significantly older and more likely to be male than were the controls. There were no significant differences in employment or country of birth. The case patients were significantly more likely to have smoked and to have drunk alcohol upon arising in the morning, and their next of kin reported that they had more family problems than did controls. Both cases and controls had high levels of asthma morbidity (Table 2). Although controls were more likely to have lost days from work, school, or usual activities, the median days lost in the preceding year was significantly higher among cases (17.5 d versus 8.5 d, p 0.01). were significantly more likely to have had persistent or very frequent asthma (more than once a week) than were controls. However, the two groups were reasonably well matched in markers of chronic asthma severity, such as hospital admissions during the preceding 12 mo. The controls were significantly more likely than the cases to have been admitted to the hospital during the month preceding death or the study index admission. excluded from analysis because of missing data were significantly more likely than those included to have had ambulance attendance (75% versus 36%, p 0.01). However, there were no significant differences between cases included and those excluded with respect to age, sex, frequency of symptoms, psychosocial problems, hospital admissions, asthma medications, or management. Similarly, there were no significant differences in these variables between cases from Melbourne and those from regional or rural Victoria. excluded from analysis were slightly older than those included (mean age: 32.4 yr versus 29.4 yr, p 0.06), but there were no significant differences in sex, hospital admissions, Pa CO2, peak expiratory flow rates, serum potassium, or salbutamol concentrations. Asthma Management and Medications Key features of asthma management for the cases and controls are summarized in Table 3. Although case patients were marginally more likely than controls not to have consulted a GP within the 12 mo preceding the study, controls were significantly more likely to have consulted multiple GPs than were case patients. The case patients were marginally less likely than controls to have a peak flow meter at home or to have kept a record of their results. Importantly, the case patients were significantly less likely than controls to have actually used a peak flow meter during the preceding 12 mo. The case patients were also significantly less likely than controls to have a written asthma action plan, and were marginally more likely to have only been given verbal instructions about what to do during a severe asthma attack. After adjustment was made for demographic and psychosocial factors and asthma severity, written action plans were found to be associated with a 70% reduction in the risk of death (Table 4). Reported use of asthma medications is presented in Table 5. Case patients were nearly four times more likely than controls to have usually taken nebulized symptomatic medication, but only a third as likely to have usually taken other inhaled symptomatic medication during the month preceding death or the study index admission. Either inhaled or nebulized symptomatic medication was usually taken by almost all subjects, and there was no significant difference between cases and controls in this respect. Case patients were nearly three times more likely to have usually taken oral steroids during the preceding month, but there were no other significant differences in usual medication. Conversely, cases were significantly less likely than controls to have used either inhaled symptomatic or nebulized medication or inhaled or oral steroids for their last attack of asthma. After adjustment for demographic and psychosocial factors and disease severity, each of the usual nebulized symptomatic medications and usual oral steroid treatments were found to be separately associated with a significantly increased risk of death (Table 4). Reported usual use of nebulized symptomatic medication either during the month preceding death or the index admission or for an attack did not change this increased risk (Table 4). The risk associated with either inhaled symptomatic or inhaled preventive medication for an attack was no longer significantly protective after adjustment. However, the use of oral steroids for an attack reduced the adjusted risk of death by 90% (Table 4). Taking oral steroids either usually during the preceding month or for an attack (thus including subjects who increased their usual dosage during the last attack) was still associated with a 30% reduction in the risk of death, but after adjustment this was no longer significant (Table 4). Management TABLE 3 ASTHMA MANAGEMENT PRACTICES AMONG CASES AND CONTROLS (n 202) p Value Did not consult a GP 5.9% 3.5% Consulted one GP 55% 36% 0.02 Consulted two or more GPs 39% 60% Used peak flow meter at home 56% 70% 0.07 Used peak flow meter in last year 41% 58% 0.04 Kept record of peak flow results 29% 36% 0.4 Used written asthma action plan 6.2% 21.9% Used verbal instructions only 21.2% 14.5% 0.21 Definition of abbreviation: GP general practitioner.

4 Abramson, Bailey, Couper, et al.: Asthma Management and Mortality 15 TABLE 4 RISK OF DEATH ASSOCIATED WITH SELECTED MANAGEMENT FEATURES AND ASTHMA MEDICATIONS ADJUSTED FOR DEMOGRAPHIC AND PSYCHOSOCIAL FACTORS AND DISEASE SEVERITY* Predictor Adjusted OR 95% CI Used peak flow meter in last year Written asthma action plan Verbal instructions only Usual oral steroid in last month Usual nebulised symptomatic medication Used nebulized symptomatic medication either usually during the last month or for an attack Used inhaled symptomatic medication for an attack Used inhaled preventive medication for an attack Used oral steroid for an attack Used oral steroid either usually during the last month or for an attack Definition of abbreviations: CI confidence interval; OR odds ratio. Separate multivariate models were fitted for each predictor (see text for details). Blood 2 -Agonist Concentrations Blood salbutamol concentrations were significantly higher in cases (n 35) than in controls (n 229). Geometric mean concentrations (95% CI) were 33.5 ng/ml (95% confidence interval [CI]: 2.4 to 464 ng/ml) in cases and 11.5 ng/ml (95% CI: 1.2 to 107 ng/ml) in controls. The highest concentrations recorded among the cases were 785, 512, 262, and 257 ng/ml, whereas the highest level among the controls was 224 ng/ml. The distributions of blood salbutamol concentrations are shown in Figure 1. The median blood terbutaline level was only 3.9 ng/ml and the maximum level was 49.3 ng/ml among controls (n 12). Terbutaline was not detected in the cases. Fenoterol was not detected in any blood specimens from either cases or controls. The final complete multivariate model of blood salbutamol concentrations is presented in Table 6. The adjusted ratio of geometric mean concentrations in cases to that in controls was Significant independent predictors of salbutamol concentrations were the dosage of nebulized or intravenous salbutamol administered in the emergency department, and ambulance attendance. Although usual oral preventive medication was left in the model to control for possible residual confounding by asthma severity, neither it nor hospital admissions during the preceding 12 mo were significantly related to blood salbutamol concentrations. The timing of specimen collection in relation to the administration of further treatment in the emergency department was not related to blood salbutamol concentrations in the controls. DISCUSSION Our results suggest that written asthma action plans can reduce the risk of death from asthma. Although these plans are a key feature of many national (18) and international guidelines, their benefit with regard to mortality is unlikely to ever be definitively confirmed by a randomized controlled trial. Nonetheless, a systematic review of the available trials concluded that written asthma management plans resulted in a significant reduction in hospitalization (23). We do not believe that written action plans were more likely to be recalled by controls simply because the latter were more likely to have been admitted to a hospital during the month preceding death or the index admission. At the time our study was conducted, there was no systematic inpatient asthma education in any of the participating hospitals. We also found that monitoring of asthma by using a peak flow meter was less likely in cases of fatal asthma than among controls, although this was no longer significant after adjustment for potential confounders. This could represent poorer care, less interest in self-monitoring, or slower appreciation of TABLE 5 REPORTED USE OF ASTHMA MEDICATION AMONG CASES AND CONTROLS* Medication (n 202) Crude OR p Value Usually during last month Inhaled symptomatic 78% 93% Nebulized symptomatic 53.1% 23.8% Either inhaled or nebulized symptomatic 90% 94% Oral symptomatic 17.7% 18.3% Inhaled preventive 60% 68.8% Oral preventive 31.4% 14.4% For last attack Inhaled symptomatic 51% 79.7% Nebulized symptomatic 47% 51.5% Either inhaled or nebulized symptomatic 64% 86.6% Oral symptomatic 5.9% 14.9% Inhaled preventive 30% 48.5% Oral preventive 17.7% 47% Definition of abbreviation: OR odds ratio. * Next of kin and controls were asked whether specific medications in each class were usually used during the month prior to the index attack or during the last attack (see text).

5 16 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL Figure 1. Distributions of blood salbutamol concentrations in cases (n 35) and controls (n 229). deterioration among the cases. There is an ongoing debate about the value of peak flow monitoring as compared with symptom-based action plans (24, 25). Although we collected considerable detail about the elements of subjects action plans, it is not known whether the plans were based on peak flow or symptom monitoring. Blood salbutamol concentrations in many cases and some controls were much higher than have been previously reported. These results negate the view that many asthma deaths occur as a result of undertreatment with bronchodilators. The accepted target range for plasma salbutamol concentrations is between 10 and 20 ng/ml in stable asthma. In one study, plasma salbutamol concentrations 14 ng/ml were found in 12% of patients presenting for emergency treatment of asthma (14). Mean plasma salbutamol concentrations of 22.7 ng/ml have been found in children with acute severe asthma who were given nebulized salbutamol (26). Adults given highdose, continuously aerosolized salbutamol for acute asthma were found to have mean serum salbutamol concentrations of 37.7 ng/ml (27). Postmortem salbutamol concentrations 47.8 ng/ml, or postmortem terbutaline concentrations 110 ng/ml, were found in 14 (21%) of 68 patients dying from asthma or COPD (15). The difference in salbutamol concentrations between cases of fatal asthma and controls in our study remained highly significant after we adjusted for further administration of salbutamol by ambulance personnel or in the emergency department. This suggests that some cases may have died from salbutamol toxicity caused by unsupervised self-administration of escalating doses. In high concentrations, salbutamol is not entirely 2 -selective, and can cause adverse cardiac (27) and metabolic (28) effects, although not to the same extent as fenoterol (29). We believe that toxic concentrations may have caused lethal tachyarrhythmias in the context of hypoxia and hypokalemia. It is quite possible that in the cases of fatal asthma, escalating doses of salbutamol were self-administered because the fatal attack was refractory to treatment at home. An alternative explanation is that the measured concentrations may have been affected by postmortem redistribution of the drug. However, salbutamol is not a lipophilic drug, and we have previously found no evidence of its significant postmortem redistribution (30). It could be argued that high salbutamol concentrations alone cannot prove that salbutamol played a role in the asthma deaths in our study, and that the most likely explanation for this finding is confounding by the acute severity of disease. Unfortunately, it was not possible to control for the severity of the fatal attack, because virtually none of the deaths occurred in settings in which objective markers such as Pa CO2, peak expiratory flow rates, or serum potassium (as a surrogate for acidosis) could be measured. However, we would argue that even in this situation, the chronic severity of the underlying asthma is a more relevant potential confounder. The difference in blood salbutamol concentrations between cases and controls remained significant after we controlled for validated markers of chronic asthma severity, such as hospital admissions during the preceding 12 mo and usual use of oral steroid medication. Case patients were significantly less likely than were controls to use oral steroids for attacks of asthma. This finding is consistent with a metaanalysis that established the use of systemic steroids early in acute asthma attacks as reducing the need for hospital admission and preventing relapse (31). Case patients were also less likely to use inhaled steroids for attacks, although this was no longer significant after adjustment was made for confounders. Clinical trials have shown that several weeks of treatment with high-dose inhaled corticosteroids is necessary to ease asthma symptoms and improve spirometric results, peak expiratory flow (32), bronchial hyperreactivity, and airway inflammation (33), and that maximal improvement can take months (34). Thus, inhaled steroids are not generally recommended in acute asthma, and our findings confirm that if used alone, they would probably not significantly reduce the risk of death. However, it is quite likely that some of our cases would have survived if they had received oral steroids early in the course of their ultimately fatal attacks. One disconcerting finding was that patients in cases of fatal asthma appeared to be less likely to use most classes of medications for the last attack. This could in part be explained by their greater use of nebulized symptomatic and oral preventive medication during the preceding month. However, it also raises the possibility of information bias, in that information TABLE 6 FINAL COMPLETE MULTIVARIATE MODEL OF BLOOD SALBUTAMOL CONCENTRATIONS* Predictor Coefficient 95% CI p Value Case: control Age, per year Sex, female: male Usual oral preventive medication Nebulised salbutamol in ED (per 5-mg dose) Intravenous salbutamol in ED (per 250- g dose) Ambulance attendance Definition of abbreviations: CI confidence interval; ED emergency department. * Coefficients represent the ratios of adjusted geometric means of subjects in first group (those with the characteristic) to those of subjects in second group (without the characteristic).

6 Abramson, Bailey, Couper, et al.: Asthma Management and Mortality 17 about cases was obtained from the next of kin, whereas controls were personally interviewed. In the South Australian study (20), proxy reports agreed well with self-reports for observed behaviors. In our study, however, the fatal attack was rarely witnessed by the next of kin, who were therefore unlikely to have been aware of exactly which medications were actually used by our cases. For this reason, we place greater emphasis on the measured salbutamol concentrations in our study than on the next-of-kin reports of symptomatic medication inhaled during attacks as reflecting the use of such medication. In fact, the agreement between reported use of salbutamol and blood concentrations of this drug was poor (data not shown). A high prevalence of smoking and psychosocial problems among patient with fatal and near fatal asthma has been previously reported (3, 4, 35). However, family problems may have been overreported by next of kin in our study as a consequence of their bereavement. The high levels of asthma morbidity and discontinuity of medical care were also not unexpected, and the two study groups were well matched for the key severity marker of hospital admissions in the year preceding death or study index admision (4, 36). The greater admission rate during the preceding month among controls probably reflects their greater use of health care services, but may have been exaggerated by recall bias. It is also possible that some cases may have delayed their presentation to the hospital, thereby delaying the institution of effective therapy and making resuscitation unavailable in the event of a cardiorespiratory arrest. Although the greater usual use of oral steroids by cases suggests some residual confounding by asthma severity, allowance for this was made in the analysis. Although there were some missing data, we do not believe that the main findings in our study were substantially affected by selection bias. There were few differences between subjects included and those excluded from the analyses. If anything, the more frequent ambulance attendance on excluded cases might be expected to have resulted in higher blood salbutamol concentrations after unsuccessful resuscitation. The excluded controls were marginally older than those included, and although this increased the age difference between cases and controls, allowance was made for it in subsequent analyses. There were no important differences in the severity of the acute asthma attack prompting the index admission between included and excluded controls. Unfortunately, this could not be assessed in the cases because of a lack of data (see the previous discussion). Furthermore, excluded controls did not have higher blood salbutamol concentrations than those included in the analysis. The inclusion of two controls who subsequently died from asthma did not substantially alter the results. Another potential source of selection bias was that although cases were identified from the entire state of Victoria, controls were recruited only from hospitals in metropolitan Melbourne, for logistic reasons. In fact, some of the controls also had residential addresses in regional or rural Victoria. There were no important differences between metropolitan and regional or rural cases. Furthermore, fitting of area of residence in the final multivariate models did not substantially alter the key study findings. Although this case control study confirms the value of some key components of modern asthma management plans, further studies are clearly required. Randomized controlled trials of selected components of such plans in high-risk asthma patients would better inform clinical practice. Our findings support the current practice of using inhaled -agonists as required, rather than giving them in regular doses on fixed schedules. We would urge physicians to be cautious about prescribing ever-increasing doses of -agonists, and urge patients not to self-administer escalating doses of -agonists during acute severe asthma attacks without first seeking assistance. Patients who require such intensive therapy should be under close medical supervision, and should also receive oxygen and systemic steroids. More widespread adoption of such sound asthma management practices should further reduce the mortality from asthma. Acknowledgment : The authors are grateful to the next of kin of the case patients, to the control patients, and to the medical practitioners who agreed to be interviewed for the study. They wish to thank Jessika Willis, Nerida Evans, and Trina Vincent for conducting the interviews. Drs. Don Campbell and Colin Robertson assisted with meetings of the clinical panel. Drs. John Coleridge, Andrew Maclean, and Graeme Thomson supervised the recruitment of controls. Dr. Henry Pinskier helped communicate with general practitioners. Police statements and autopsy reports for cases were made available by the office of the Victorian State Coroner, Graham Johnstone. David Lescun provided information from Ambulance Service Victoria files. Andrew Stanish prepared Figure 1. References 1. Abramson MJ, Couper F, Campbell DA. Reviewing mortality. Clin. Asthma Rev 1998;2: Sears MR, Rea HH, Beaglehole R, Gillies AJ, Holst PE, O Donnell TV, Rothwell RP, Sutherland DC. Asthma mortality in New Zealand: a two year national study. NZ Med J 1985;98: Robertson CF, Rubinfeld AR, Bowes G. Deaths from asthma in Victoria: a 12 month survey. Med J Aust 1990;152: Rea HH, Scragg R, Jackson R, Beaglehole R, Fenwick J, Sutherland DC. A case control study of deaths from asthma. Thorax 1986;41: Crane J, Pearce N, Flatt A, Jackson R, Burgess C, Kwong T, Ball M, Beasley R. Prescribed fenoterol and death from asthma in New Zealand : a case control study. Lancet 1989;1: Pearce N, Grainger J, Atkinson M, Crane J, Burgess C, Culling C, Windom H, Beasley R. Case control study of prescribed fenoterol and death from asthma in New Zealand Thorax 1990;45: Grainger J, Woodman K, Pearce N, Crane J, Burgess C, Keane A, Beasley R. Prescribed fenoterol and death from asthma in New Zealand : a further case control study. Thorax 1991;46: Campbell DA, McLennan G, Coates JR, Frith PA, Gluyas PA, Latimer KM, Luke CG, Martin AJ, Roder DM, Ruffin RE. A comparison of asthma deaths and near-fatal asthma attacks in South Australia. Eur Respir J 1994;7: Ryan G, Musk AW, Perera DM, Stock H, Knight JL, Hobbs MS. Risk factors for death in patients admitted to hospital with asthma: a follow-up study. Aust NZ J Med 1991;21: Garrett JE, Lanes SF, Kolbe J, Rea HH. Risk of severe life threatening asthma and -agonist type: an example of confounding by severity. Thorax 1996;51: Pearce N, Beasley R, Crane J, Burgess C, Jackson R. End of the New Zealand asthma mortality epidemic. Lancet 1995;345: Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, Boivin JF, McNutt M, Buist AS, Rebuck AS. The use of agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326: Pearce N, Hensley MJ. Epidemiologic studies of beta agonists and asthma deaths. Epidemiol Rev 1998;20: Janson C, Boe J, Boman G, Mossberg B, Svedmyr N. Bronchodilator intake and plasma levels on admission for severe acute asthma. Eur Respir J 1992;5: Lindsjo M, Boman G, Lindstrom B, Stranberg K, Wiholm BE. Postmortem concentrations of salbutamol, terbutaline and theophylline in asthma patients. Eur J Respir Dis 1987;71: Beasley R, Burgess C, Pearce N, Woodman K, Crane J. Confounding by severity does not explain the association between fenoterol and asthma death. Clin Exp Allergy 1994;24: Ernst P, Habbick B, Suissa S, Hemmelgarn B, Cockcroft D, Buist AS, Horwitz RI, McNutt M, Spitzer WO. Is the association between inhaled beta-agonist use and life threatening asthma because of confounding by severity? Am Rev Respir Dis 1993;148: Woolcock AJ, Rubinfeld AR, Seale JP, Landau LI, Antic R, Mitchell C, Rea HH, Zimmerman P. Asthma management plan Med J Aust 1989;151: Comino EJ, Mitchell CA, Bauman A, Henry R, Robertson CF, Abram-

7 18 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL son M, Ruffin RE, Landau LI. Asthma management in Eastern Australia 1990 and 1993 Med J Aust 1996;164: Campbell DA, McLennan G, Coates JR, Frith PA, Gluyas PA, Latimer KM, Martin AJ, Roder DM, Ruffin RE, Scarce D. Near fatal asthma attacks: the reliability of descriptive information collected from close acquaintances. Thorax 1993;48: Couper FJ, Drummer OH. Gas chromatography-mass spectrometric determination of 2 agonists in postmortem blood: application in forensic medicine. J Chromatogr B Biomed Appl 1996;685: Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS system for mixed models. Cary, NC: SAS Institute Inc.; Gibson PG, Coughlan J, Wilson AJ, Abramson M, Bauman A, Hensley MJ, Walters EH. Self-management education and regular practitioner review for adults with asthma (Cochrane Review). In: The Cochrane Library, Issue 4. Oxford, UK: Update Software; Cowie RL, Revitt SG, Underwood MF, Field SK. The effect of a peak flow based action plan in the prevention of exacerbations of asthma. Chest 1997;112: Turner MO, Taylor D, Bennett R, Fitzgerald JM. A randomised trial comparing peak expiratory flow and symptom self management plans for patients with asthma attending a primary care clinic. Am J Respir Crit Care Med 1998;157: Penna AC, Dawson KP, Manglick P, Tam J. Systemic absorption of salbutamol following nebulizer delivery in acute asthma. Acta Paediatr 1993;82: Lin RY, Smith AJ, Hergenroeder P. High serum albuterol levels and tachycardia in adult asthmatics treated with high-dose continuously aerosolized albuterol. Chest 1993;103: Bremner P, Siebers R, Crane J, Beasley R, Burgess C. Partial vs full betareceptor antagonism: a clinical study of inhaled albuterol and fenoterol. Chest 1996;109: Bremner P, Burgess C, Beasley R, Woodman K, Marshall S, Crane J, Pearce N. Nebulized fenoterol causes greater cardiovascular and hypokalaemic effects than equivalent bronchodilator doses of salbutamol in asthmatics. Respir Med 1992;86: Couper FJ, Drummer OH. Postmortem stability and interpretation of 2-agonist concentrations. J Forensic Sci 1999;44: Rowe BH, Keller JL, Oxman AD. Effectiveness of steroid therapy in acute exacerbations of asthma: a meta-analysis. Am J Emerg Med 1992;10: Kerstjens HA, Brand PL, de Jong PM, Koeter GH, Postma DS, The Dutch CNSLD Study Group. Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. Thorax 1994;49: Laitinen LA, Laitinen A, and Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992;90: Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O Byrne PM, Hargreave FE. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990; 142: Kolbe J, Vamos M, Fergusson W. Socio-economic disadvantage, quality of medical care and admission for acute severe asthma. Aust NZ J Med 1997;27: Crane J, Pearce N, Burgess C, Woodman K, Robson B, Beasley R. Markers of risk of asthma death or readmission in the 12 months following a hospital admission for asthma. Int J Epidemiol 1992;21: